Find Octreotide Acetate manufacturers, exporters & distributors on PharmaCompass

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

44 API Suppliers, 27 USDMF, 6 CEP/COS, 4 JDMF, 5 EU WC, 1 KDMF, 20 NDC API, 25 Listed Suppliers

44 API Suppliers
27 USDMF
6 CEP/COS
4 JDMF
5 EU WC
1 KDMF
20 NDC API
25 Listed Suppliers

DEVELOPMENTS

23 Drugs in Development

23 Drugs in Development

FINISHED DOSAGE FORMULATIONS

238 FDF Dossiers, 61 FDA Orange Book, 92 Europe, 11 Canada, 48 Australia, 8 South Africa, 18 Listed Dossiers

238 FDF Dossiers
61 FDA Orange Book
92 Europe
11 Canada
48 Australia
8 South Africa
18 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 0.05MG BASE/ML, INJECTABLE;INJECTION - EQ 0.1MG BASE/ML, INJECTABLE;INJECTION - EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 0.5MG BASE/ML, INJECTABLE;INJECTION - EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;SUBCUTANEOUS - 7MG/2.8ML (2.5MG/ML)

drugProductComposition
INJECTABLE;INJECTION - EQ 0.05MG BASE/ML
INJECTABLE;INJECTION - EQ 0.1MG BASE/ML
INJECTABLE;INJECTION - EQ 0.2MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
INJECTABLE;INJECTION - EQ 0.5MG BASE/ML
INJECTABLE;INJECTION - EQ 1MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;SUBCUTANEOUS - 7MG/2.8ML (2.5MG/ML)

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 13 SPI Pharma, 1 Faran Shimi Pharmaceutical, 1 Pfanstiehl, 2 Actylis, 1 BASF, 1 Finar, 2 Gangwal Chemicals, 1 Ingredion Pharma Solutions, 2 Kerry, 2 Microlex e.U, 1 Pluviaendo, 3 Roquette, 1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 1 Sigachi Industries

relatedExcipients
1 Rochem International Inc
13 SPI Pharma
1 Faran Shimi Pharmaceutical
1 Pfanstiehl
2 Actylis
1 BASF
1 Finar
2 Gangwal Chemicals
1 Ingredion Pharma Solutions
2 Kerry
2 Microlex e.U
1 Pluviaendo
3 Roquette
1 Shanghai Shenmei Pharmaceutical Technology Co., Ltd
1 Shijiazhuang Huaxu Pharmaceutical
1 Sigachi Industries

EXCIPIENTS BY APPLICATIONS

17 Fillers, Diluents & Binders, 10 Chewable & Orodispersible Aids, 9 Direct Compression, 9 Taste Masking, 7 Parenteral, 4 Co-Processed Excipients, 3 Disintegrants & Superdisintegrants, 3 Granulation, 2 API Stability Enhancers, 1 Thickeners and Stabilizers, 1 Topical

excipientsByApplications
17 Fillers, Diluents & Binders
10 Chewable & Orodispersible Aids
9 Direct Compression
9 Taste Masking
7 Parenteral
4 Co-Processed Excipients
3 Disintegrants & Superdisintegrants
3 Granulation
2 API Stability Enhancers
1 Thickeners and Stabilizers
1 Topical

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 38 NEWS #PharmaBuzz

media
2 DATA COMPILATION #PharmaFlow
38 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 79 Finished Drug Prices, 10 Annual Reports

globalSalesInformation
3 US Medicaid Prescriptions
79 Finished Drug Prices
10 Annual Reports

MARKET PLACE

15 APIs, 16 FDF Dossiers

marketPlace
15 APIs
16 FDF Dossiers

PATENTS & EXCLUSIVITIES

15 US Patents, 1 US Exclusivities

patents
15 US Patents
1 US Exclusivities

REF. STANDARDS & IMPURITIES

2 USP , 6 Others

otherSolutions
2 USP
6 Others

Bachem Octreotide Acetate

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 289,821

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

238

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

23DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

58,319,474

Annual Reports (USD Million)

13,488

Finished Drug Prices

34 RELATED EXCIPIENT COMPANIES

66EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Sandostatin, 79517-01-4, Nsc672461, Sandostatin (tn), Acetic acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-n-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide, Octreotide acetate (usp)

Molecular Formula

C₅₁H₇₀N₁₀O₁₂S₂

Molecular Weight

1079.3 g/mol

InChI Key

XQEJFZYLWPSJOV-UHFFFAOYSA-N

A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula.

1 2D Structure

Octreotide Acetate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

acetic acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

2.1.2 InChI

InChI=1S/C49H66N10O10S2.C2H4O2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41;1-2(3)4/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64);1H3,(H,3,4)

2.1.3 InChI Key

XQEJFZYLWPSJOV-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O.CC(=O)O

2.2 Synonyms

2.2.1 MeSH Synonyms

1. Compound 201 995

2. Compound 201-995

3. Compound 201995

4. Octreotide

5. Octreotide Acetate

6. Octreotide Acetate Salt

7. San 201 995

8. San 201-995

9. San 201995

10. Sandostatin

11. Sandostatine

12. Sandoz 201 995

13. Sandoz 201-995

14. Sandoz 201995

15. Sm 201 995

16. Sm 201-995

17. Sm 201995

18. Sms 201 995

19. Sms 201-995

20. Sms 201995

2.2.2 Depositor-Supplied Synonyms

1. Sandostatin

2. 79517-01-4

3. Nsc672461

4. Sandostatin (tn)

5. Acetic Acid;10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-n-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

6. Octreotide Acetate (usp)

7. Schembl58453

8. Chembl2000504

9. Hms3748c05

10. Bcp04661

11. Nsc671663

12. Nsc-671663

13. Nsc-672461

14. Acetic Acid;(4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

15. D-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-[(1r,2r)-2-hydroxy-1-(hydroxymethyl)propyl]-l-cysteinamide Cyclic (2-7)-disulfide Acetate

16. 10-(4-aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-n-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide Acetate

17. D06495

18. 10-(4-aminobutyl)-19-[(2-amino-3-phenyl-propanoyl)amino]-16-benzyl-7-(1-hydroxyethyl)-n-[2-hydroxy-1-(hydroxymethyl)propyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide

19. D-phenylalanyl-l-hemicystyl-l-phenylalanyl-d-trytophyl-l-lysyl-l-threonyl-l-hemicystyl-l-threoninol, Acetate

2.3 Create Date

2005-03-26

3 Chemical and Physical Properties

Molecular Formula	C₅₁H₇₀N₁₀O₁₂S₂
Molecular Weight	1079.3 g/mol
Hydrogen Bond Donor Count	14
Hydrogen Bond Acceptor Count	16
Rotatable Bond Count	17
Exact Mass	1078.46161005 g/mol
Monoisotopic Mass	1078.46161005 g/mol
Topological Polar Surface Area	420 Å²
Heavy Atom Count	75
Formal Charge	0
Complexity	1780
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	10
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Information

1 of 6
Drug Name	Octreotide acetate
Drug Label	Octreotide acetate injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered acetate solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octreotide acetate, known...
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market Status	Prescription
Company	Sun Pharm Inds; Teva Pharms Usa; Fresenius Kabi Usa; Sagent Pharms; Eurohlth Intl; Wockhardt Usa

2 of 6
Drug Name	Sandostatin
PubMed Health	Octreotide (Injection)
Drug Classes	Endocrine-Metabolic Agent
Drug Label	Sandostatin (octreotide acetate) Injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered lactic acid solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octre...
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market Status	Prescription
Company	Novartis

3 of 6
Drug Name	Sandostatin lar
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 30mg base/vial; eq 10mg base/vial; eq 20mg base/vial
Market Status	Prescription
Company	Novartis

4 of 6
Drug Name	Octreotide acetate
Drug Label	Octreotide acetate injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered acetate solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octreotide acetate, known...
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market Status	Prescription
Company	Sun Pharm Inds; Teva Pharms Usa; Fresenius Kabi Usa; Sagent Pharms; Eurohlth Intl; Wockhardt Usa

5 of 6
Drug Name	Sandostatin
PubMed Health	Octreotide (Injection)
Drug Classes	Endocrine-Metabolic Agent
Drug Label	Sandostatin (octreotide acetate) Injection, a cyclic octapeptide prepared as a clear sterile solution of octreotide, acetate salt, in a buffered lactic acid solution for administration by deep subcutaneous (intrafat) or intravenous injection. Octre...
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 0.2mg base/ml; eq 1mg base/ml; eq 0.1mg base/ml; eq 0.05mg base/ml; eq 0.5mg base/ml
Market Status	Prescription
Company	Novartis

6 of 6
Drug Name	Sandostatin lar
Active Ingredient	Octreotide acetate
Dosage Form	Injectable
Route	Injection
Strength	eq 30mg base/vial; eq 10mg base/vial; eq 20mg base/vial
Market Status	Prescription
Company	Novartis

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Gastrointestinal Agents

Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. (See all compounds classified as Gastrointestinal Agents.)

Antineoplastic Agents, Hormonal

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)

API SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Australia

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

South Africa

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us